Plain-English translation of NCT06671093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing Tune-401, an experimental medication that uses a new approach called epigenetic gene silencing to treat chronic hepatitis B. The medication is delivered directly into the bloodstream using special lipid nanoparticles (tiny fat-based carriers). Researchers want to understand how safe this treatment is, how your body processes it, and how well it works.
Currently available hepatitis B treatments help manage the virus but don't cure it for most people. This trial is exploring whether this new gene-silencing approach could offer a different way to fight the virus and potentially work better than existing options.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the experimental medication during clinic visits. The study has two parts: first, researchers will test increasing doses to find the safest level, and then they'll test the medication given once or several times. You'll have blood tests and medical check-ups to monitor how your body responds and how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Hong Kong
Moldova
New Zealand